Clinical trial
Safety, Blood Levels and Effects of GW642444
NCT00469040 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00469040 |
|---|---|
| Title | Safety, Blood Levels and Effects of GW642444 |
| Official title | A Randomised, Double-blind, Placebo-controlled, Parallel-group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Extra-pulmonary Pharmacodynamics of Inhaled Doses of GW642444M Formulated With Magnesium Stearate in Healthy Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | GW642444M for 14 days |
| Enrollment | 36 |
| Start date | Feb 28, 2007 |
| Primary completion | Apr 16, 2007 |
| Completion | Apr 16, 2007 |
| First posted | May 4, 2007 |
| Last update posted | Aug 4, 2017 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: